Kennel

Kennel Connection Expands Petwealth Diagnostics at Expo West After Strong Intergroom Debut

Kennel Connection Showcases Petwealth Diagnostics at Pet Boarding & Daycare Expo West After Strong Intergroom Debut Kennel Connection, a leading pet care facility management software provider and part of 100GROUP, is expanding its national rollout of an exclusive diagnostic partnership…

Read MoreKennel Connection Expands Petwealth Diagnostics at Expo West After Strong Intergroom Debut
Octave

Octave Bioscience Accelerates Precision Neurology Expansion Through Strategic Leadership Appointment

Octave Bioscience Strengthens Precision Neurology Strategy with Appointment of Zachary Fernandes as Vice President of Business Development Octave Bioscience, a commercial-stage precision medicine company dedicated to advancing biomarker-driven solutions for multiple sclerosis (MS), Parkinson’s disease, and other neurodegenerative disorders, has…

Read MoreOctave Bioscience Accelerates Precision Neurology Expansion Through Strategic Leadership Appointment
Insulet

Insulet Issues Voluntary Medical Device Correction Affecting Certain Omnipod® Pods

Insulet Launches Voluntary Medical Device Correction for Certain Omnipod® Pods Due to Potential Insulin Under-Delivery Risk Insulet Corporation, a leading manufacturer of tubeless insulin delivery systems, has announced a voluntary Medical Device Correction affecting specific lots of Omnipod® 5, Omnipod…

Read MoreInsulet Issues Voluntary Medical Device Correction Affecting Certain Omnipod® Pods
TFG-001

TFG-001 Cell Therapy Shows Promise in Parkinson’s Disease

TreeFrog Therapeutics Unveils Promising Preclinical Data for TFG-001 Cell Therapy in Parkinson’s Disease TreeFrog Therapeutics, a regenerative medicine biotechnology company focused on developing next-generation cell therapies, has announced encouraging new preclinical findings for its lead Parkinson’s disease candidate, TFG-001, ahead…

Read MoreTFG-001 Cell Therapy Shows Promise in Parkinson’s Disease
Fulgent

Fulgent Announces ASCO 2026 Abstract for FID-007 in Head & Neck Cancer Session

Fulgent Genetics Announces Full Abstract Publication of FID-007 Combination Therapy in Head and Neck Cancer at ASCO 2026 Fulgent Genetics, a technology-driven life sciences company with established laboratory services and an expanding therapeutic development division, announced that the full abstract…

Read MoreFulgent Announces ASCO 2026 Abstract for FID-007 in Head & Neck Cancer Session